The following is a summary of "Advances and challenges in targeted therapies for HER2-amplified colorectal cancer," published ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors. It not only holds potential to deliver a new generation of ADC therapies characterized ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

That same year, based on a pooled analysis of two phase 2 single-arm studies, the drug followed with a Chinese nod to treat platinum-refractory bladder cancer with HER2 overexpression at IHC 2+ or ...

Learn about HER2-positive breast cancer, its symptoms, causes, and prevention tips. Understand early signs and available ...

Five-year survival for people with metastatic disease is less than 5%. HER2 overexpression or gene amplification rates range from 4% to 5% for intrahepatic cholangiocarcinoma, 17% to 19% for ...

HER2 overexpression is linked to aggressive tumor growth, a poorer prognosis, and reduced response to some conventional therapies, making it a highly sensitive target for cancer treatment.

HER2 overexpression is linked to aggressive tumor growth, a poorer prognosis, and reduced response to some conventional therapies, making it a highly sensitive target for cancer treatment.

HER2 overexpression or amplification is a known poor prognostic indicator in various malignancies and has been previously studied in EMPD, albeit with limited sample sizes. The rates of HER2 ...